ZIOPHARM Oncology Inc (ZIOP) CEO Laurence James Neil Cooper Purchases 6440 Shares of Stock .

Oncology

1 Views

        

ZIOPHARM Oncology Inc (NASDAQ:ZIOP) CEO Laurence James Neil Cooper purchased 6,440 shares of the stock in a transaction on Wednesday, November 8th. The stock was acquired at an average cost of $4.68 per share, with a total value of $30,139.20. Following the acquisition, the chief executive officer now owns 1,083,731 shares of the company’s stock, valued at approximately $5,071,861.08. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Shares of ZIOPHARM Oncology Inc (NASDAQ:ZIOP) traded down $0.17 during mid-day trading on Friday, reaching $4.57. The company had a trading volume of 2,691,670 shares, compared to its average volume of 1,360,851. ZIOPHARM Oncology Inc has a 52-week low of $4.03 and a 52-week high of $7.88.

ZIOPHARM Oncology (NASDAQ:ZIOP) last released its quarterly earnings results on Monday, November 6th. The biotechnology company reported ($0.13) earnings per share for the quarter, hitting the consensus estimate of ($0.13). The company had revenue of $1.60 million for the quarter, compared to analysts’ expectations of $1.66 million. The business’s quarterly revenue was up .0% on a year-over-year basis. During the same period in the previous year, the business posted ($0.11) EPS. analysts predict that ZIOPHARM Oncology Inc will post -0.54 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This piece was originally published by TrueBlueTribune and is owned by of TrueBlueTribune. If you are accessing this piece on another site, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.truebluetribune.com/2017/11/19/insider-buying-ziopharm-oncology-inc-ziop-ceo-acquires-6440-shares-of-stock.html.

A number of hedge funds have recently modified their holdings of ZIOP. Vanguard Group Inc. grew its holdings in ZIOPHARM Oncology by 7.6% in the 2nd quarter. Vanguard Group Inc. now owns 7,864,470 shares of the biotechnology company’s stock worth $48,917,000 after buying an additional 553,933 shares in the last quarter. State Street Corp raised its stake in ZIOPHARM Oncology by 12.8% during the 2nd quarter. State Street Corp now owns 4,556,264 shares of the biotechnology company’s stock valued at $28,342,000 after purchasing an additional 517,057 shares during the period. Morgan Stanley raised its stake in ZIOPHARM Oncology by 19.5% during the 1st quarter. Morgan Stanley now owns 1,989,175 shares of the biotechnology company’s stock valued at $12,610,000 after purchasing an additional 324,774 shares during the period. California Public Employees Retirement System raised its stake in ZIOPHARM Oncology by 95.9% during the 1st quarter. California Public Employees Retirement System now owns 435,532 shares of the biotechnology company’s stock valued at $2,541,000 after purchasing an additional 213,166 shares during the period. Finally, Canada Pension Plan Investment Board acquired a new position in shares of ZIOPHARM Oncology in the second quarter worth $1,010,000. 41.88% of the stock is owned by institutional investors and hedge funds.

A number of equities research analysts recently commented on ZIOP shares. Zacks Investment Research raised ZIOPHARM Oncology from a “hold” rating to a “buy” rating and set a $5.25 target price for the company in a report on Friday, November 10th. HC Wainwright restated a “buy” rating and issued a $9.50 price objective on shares of ZIOPHARM Oncology in a research report on Tuesday, November 7th. ValuEngine cut ZIOPHARM Oncology from a “hold” rating to a “sell” rating in a research report on Friday, September 15th. Finally, BidaskClub cut ZIOPHARM Oncology from a “hold” rating to a “sell” rating in a research report on Monday, August 14th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. ZIOPHARM Oncology presently has an average rating of “Hold” and an average target price of $12.58.

About ZIOPHARM Oncology

ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.

Receive News & Ratings for ZIOPHARM Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology Inc and related companies with MarketBeat.com's FREE daily email newsletter.